Work

BT062, An Antibody-Drug Conjugate Directed Against CD138, Shows Clinical Activity In a Phase I Study In Patients with Relapsed or Relapsed/Refractory Multiple Myeloma

Year: 2010

Type: article

Study design: Clinical Trial

Source: Blood

DOI: 10.1182/blood.v116.21.3060.3060

Authors: Sundar Jagannath, Asher A. Chanan-Khan, Leonard T Heffner, David Avigan, Robert J Lutz, Christoph Uherek, Frank Osterroth, Markus Ruehle, Thomas Haeder, Gabriele Niemann, Andrea Wartenberg-Demand, Nikhil C. Munshi, Kenneth C. Anderson

Institutions: Icahn School of Medicine at Mount Sinai, Roswell Park Comprehensive Cancer Center, Winship Cancer Institute, Beth Israel Deaconess Medical Center, ImmunoGen (United States), Biotest (Germany), Harvard University, VA Boston Healthcare System, Dana-Farber Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2549897316

FWCI: 0.992

Cites:

Cited by: 12

Related to: 10